NZ-97

NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056) -induced lung injury and Bleomycin (HY-108345) -induced lung fibrosis in mice model[1].

Product Specifications

UNSPSC

12352005

Target

Dipeptidyl Peptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nz-97.html

Purity

99.43

Solubility

10 mM in DMSO

Smiles

CCCCCCCCN(C[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CC1=CC=C(C=C1)CNC(OCCOC23CC4CC(CC(C4)(C3)[C@@H](C(N5[C@@H](C[C@@H]6C[C@@H]65)C#N)=O)N)C2)=O

Molecular Formula

C43H67N5O9

Molecular Weight

798.02

References & Citations

[1]Shao S, et al., Pharmacological expansion of type 2 alveolar epithelial cells promotes regenerative lower airway repair. Proc Natl Acad Sci U S A. 2024 Apr 16;121 (16) :e2400077121.